A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma (Q33961394)

30 July 2017

title

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma (English)

1 reference

pancreatic adenocarcinoma

30 July 2017

1 reference

1 reference

1 reference

1 reference

P Rougier

1

1 reference

30 July 2017

A Adenis

2

1 reference

30 July 2017

M Ducreux

3

1 reference

30 July 2017

M de Forni

4

1 reference

30 July 2017

J Bonneterre

5

1 reference

30 July 2017

M Dembak

6

1 reference

30 July 2017

P Clouet

7

1 reference

30 July 2017

A Lebecq

8

1 reference

30 July 2017

P Baille

9

1 reference

30 July 2017

F Lefresne-Soulas

10

1 reference

30 July 2017

C Blanc

11

1 reference

30 July 2017

J P Armand

12

1 reference

30 July 2017

publication date

1 May 2000

1 reference

European Journal of Cancer

30 July 2017

published in

1 reference

30 July 2017

volume

36

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1016-1025

1 reference

Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Use of 5-Fluorouracil in Disseminated Solid Neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Mechanism of action of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Promotion of microtubule assembly in vitro by taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Activity of cisplatin in adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900072-1

7 January 2021

10.1016/S0959-8049(00)00072-1

Identifiers

DOI

1 reference

30 July 2017

1 reference